<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2021000400006</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2021000400006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultados en salud y aspectos farmaco-económicos del tratamiendo con PRGF-Endoret en ojo seco]]></article-title>
<article-title xml:lang="en"><![CDATA[Health outcomes and pharmaco-economic aspects of the treatment with PRGF-Endoret in dry eye]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gea-Navarrete]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montero-Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gallego-Lago]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santiuste-Román]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montesinos-Ortí]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soler-Company]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Arnau de Vilanova-Llíria Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Arnau de Vilanova-Llíria Servicio de Oftalmología ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>31</volume>
<numero>4</numero>
<fpage>357</fpage>
<lpage>360</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2021000400006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2021000400006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2021000400006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Evaluar la efectividad, la seguridad y la satisfacción del tratamiento con colirio de PRGF-Endoret en pacientes con ojo seco patológico, así como los costes de adquisición, elaboración y dispensación en comparación con suero autólogo.  Metodología: Estudio observacional retrospectivo. Se incluyeron todos los pacientes para los que se prescribió PRGFEndoret entre febrero de 2019 y enero de 2020, para el tratamiento de varios trastornos con sequedad ocular como síntoma. Los datos demográficos y clínicos se obtuvieron del historial médico electrónico (Orion Clinic). Además, se realizó una encuesta anónima evaluando la frecuencia de varios síntomas, la efectividad, seguridad y satisfacción con el tratamiento.  Resultados: Se estudiaron 24 pacientes. Un 62,5% eran mujeres, con una mediana de edad de 64 años. Un 79% habían sido diagnosticados de queratitis y/o úlcera corneal. En el 75% de los casos la evolución clínica fue favorable a los tres meses. El 100% de los pacientes estaban satisfechos. En cuanto a los síntomas, el 100% percibieron una mejoría en la sequedad ocular, el 80% en la molestia a la luz y el 60% en el dolor. El 50% de los pacientes había recibido previamente suero autólogo, de los cuales el 82% tuvo una evolución favorable con el cambio de tratamiento.  Conclusión: PRGF-Endoret mejoró los síntomas del ojo seco en el grupo de pacientes tratado, siendo efectivo y seguro y proporcionando alta satisfacción. Los costes directos sanitarios son mayores que con la alternativa de suero autólogo, pero son necesarios nuevos estudios que evalúen los costes indirectos evitados y la calidad de vida proporcionada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objective: To evaluate the efficacy, safety and costs of acquisition, preparation and dispensing of PRGF-Endoret eye drops, as well as patient satisfaction in patients with pathological dry eye.  Methodology: Retrospective observational study. All patients for whom PRGF-Endoret were prescribed between February 2019 and January 2020 for the treatment of various disorders with ocular sequence as a symptom were included. Demographic and clinical data were obtained from the electronic medical record (Orion Clinic). In addition, an anonymous survey was carried out evaluating the frequency of various symptoms, the difficulty, safety and satisfaction with the treatment.  Results: 24 patients were studied. 62.5% were women, with a median age of 64 years. 79% had been diagnosed with keratitis and/or corneal ulcer. In 75% of the cases, the clinical evolution was favourable after three months. 100% of the patients were satisfied. Regarding symptoms, 100% perceived an improvement in dry eyes, 80% in light discomfort and 60% in pain. 50% of the patients had previously received autologous serum, of which 82% had a favourable evolution with the change of treatment.  Conclusion: PRGF-Endoret improved dry eye symptoms in our patients being effective and safe, with high satisfaction from the patients. Although evaluating direct healthcare costs is more expensive than the autologous serum alternative, quality of life and indirect costs should be considered.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de ojo seco]]></kwd>
<kwd lng="es"><![CDATA[factores de crecimiento]]></kwd>
<kwd lng="es"><![CDATA[suero autólogo]]></kwd>
<kwd lng="es"><![CDATA[colirio]]></kwd>
<kwd lng="es"><![CDATA[solución oftálmica]]></kwd>
<kwd lng="en"><![CDATA[Dry eye syndromes]]></kwd>
<kwd lng="en"><![CDATA[growth factors]]></kwd>
<kwd lng="en"><![CDATA[eye drops]]></kwd>
<kwd lng="en"><![CDATA[autologous serum]]></kwd>
<kwd lng="en"><![CDATA[ophthalmic solutions]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sainz de la Maza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en hemoderivados en el tratamiento del síndrome de ojo seco]]></article-title>
<source><![CDATA[Superf Ocul Córnea]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>5-15</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klenkler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sheardown]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Growth factors in the tear film: Role in tissue maintenance, wound healing, and ocular pathology]]></article-title>
<source><![CDATA[Ocul Surf]]></source>
<year>2007</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>228-39</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monroy]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Pflugfelder]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytokines and tear function in ocular surface disease]]></article-title>
<source><![CDATA[Advances in Experimental Medicine and Biology]]></source>
<year>1998</year>
<page-range>461-9</page-range><publisher-loc><![CDATA[Boston, MA ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marfurt]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Kruse]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tervo]]></surname>
<given-names><![CDATA[TMT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corneal nerves: Structure, contents and function]]></article-title>
<source><![CDATA[Exp Eye Res]]></source>
<year>2003</year>
<volume>76</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>521-42</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pflugfelder]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dursun]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[DQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dry eye and delayed tear clearance: &#8220;A call to arms.&#8221;]]></article-title>
<source><![CDATA[Advances in Experimental Medicine and Biology]]></source>
<year>2002</year>
<page-range>739-43</page-range><publisher-loc><![CDATA[Boston, MA ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Albenz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Begley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caffery]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schaumberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of dry eye disease: Report of the epidemiology subcommittee of the international Dry Eye WorkShop (2007)]]></article-title>
<source><![CDATA[Ocul Surf]]></source>
<year>2007</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>93-107</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="">
<collab>Sociedad Española de Oftalmología</collab>
<source><![CDATA[Patologías frecuentes: Ojo seco]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Ares]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Gude]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of and associated factors for dry eye in a Spanish adult population (The Salnes Eye Study)]]></article-title>
<source><![CDATA[Ophthalmic Epidemiol]]></source>
<year>2009</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-21</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vicente-Herrero]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Iñiguez de la Torre]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Terradillos-García]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[López González]]></surname>
<given-names><![CDATA[ÁA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome del ojo seco. Factores de riesgo laboral, valoración y prevención]]></article-title>
<source><![CDATA[Semergen]]></source>
<year>2014</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-103</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galvez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andreu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ojo seco: diagnóstico y tratamiento]]></article-title>
<source><![CDATA[MspsiGobEs]]></source>
<year>1998</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>117-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geerling]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Dart]]></surname>
<given-names><![CDATA[JKG]]></given-names>
</name>
<name>
<surname><![CDATA[Cree]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Khaw]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells]]></article-title>
<source><![CDATA[Investig Ophthalmol Vis Sci]]></source>
<year>2001</year>
<volume>42</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>948-56</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noecker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of common ophthalmic preservatives on ocular health]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2001</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>205-15</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Etchaberry]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colirio de suero autólogo]]></article-title>
<source><![CDATA[Offarm]]></source>
<year>2007</year>
<volume>26</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>100-1005</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riestra]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Herreros]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Merayo-Lloves]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma rico en plaquetas en superficie ocular]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol]]></source>
<year>2016</year>
<volume>91</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>475-90</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Plandolit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Freire]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Grau]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Durán]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of plasma rich in growth factors for the treatment of dry eye]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2011</year>
<volume>30</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1312-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Begley]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Caffery]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2002</year>
<volume>21</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>664-70</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merayo-Lloves]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez-Avila]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Riestra]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Begoña]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Orive]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye]]></article-title>
<source><![CDATA[Ophthalmic Res]]></source>
<year>2016</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>68-73</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Plandolit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Freire]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Etxebarría]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Durán]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2010</year>
<volume>29</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>843-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez-Avila]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Merayo-Lloves]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Gutierrez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jurado]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Muruzabal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma rich in growth factors for the treatment of dry eye after LASIK surgery]]></article-title>
<source><![CDATA[Ophthalmic Res]]></source>
<year>2018</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>80-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Muruzabal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fuente]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Riestra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Merayo-Lloves]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Orive]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model]]></article-title>
<source><![CDATA[Exp Eye Res]]></source>
<year>2016</year>
<volume>151</volume>
<page-range>115-21</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
